Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- Inflation Continues to Challenge U.S. Economy
- Corporate America is making a trillion-dollar mistake about retirement
- Anthropic officially sets the stage for an IPO valuing the company north of $1 trillion
- 2027 will be an ‘inflection year’ as R2, autonomy ramp up
- Cash, Debt, and Corporate Investment
- Goldman Sachs, Citi among banks said to commit $270 million to stablecoin venture
- Should a widow leave her late partner’s home to her stepkids — or cut off contact with them?
- AI financing remains strong despite market jitters
Wednesday, November 11
